JAMA/ LinkedIn
Sep 1, 2025, 07:40
JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF
Journal of the American Medical Association (JAMA) made a noteworthy post on LinkedIn:
“In patients with cardiometabolic HFpEF, semaglutide and tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.”
Read the full article here:
Article: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Nils Krüger, Sebastian Schneeweiss, Kenshiro Fuse, Sofiya Matseyko, Sushama Kattinakere Sreedhara, Georg Hahn, Heribert Schunkert, Shirley V. Wang
Follow the newest insights in hematology with Hemostasis Today.
-
Jun 11, 2026, 14:56Maia Meier: You Cannot Diagnose What You Do Not Recognize
-
Jun 11, 2026, 14:48Konstantin Yenkoyan: When Does the Developing Brain Need Iron Most? – Implications for Autism
-
Jun 11, 2026, 14:43Shadi Tabibian: Normal Tests, Abnormal Bleeding
-
Jun 11, 2026, 14:38Jan Sloves: Iliac Vein Compression – Why Position Matters More Than We Think
-
Jun 11, 2026, 14:30Levi Tomitšik: Contributing to Thrombosis Research as a Volunteer Donor
-
Jun 11, 2026, 12:58Joseph R. Shaw: Beyond Predictable Pharmacokinetics in DOAC Therapy
-
Jun 11, 2026, 12:40Khechar N Paudel: The Nepal Stroke Project Brings Evidence-Based Stroke Care to Remote Communities
-
Jun 11, 2026, 12:35Sergey Badalyan: EHA2026 Opening Ceremony – The Importance of Building Communities, Not Projects
-
Jun 11, 2026, 12:15Welcome to EHA 2026